Back to Search
Start Over
Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis: Data From a Nationwide Analysis.
- Source :
-
Circulation . 1/28/2020, Vol. 141 Issue 4, p260-268. 9p. - Publication Year :
- 2020
-
Abstract
- <bold>Background: </bold>Two competing transcatheter aortic valve replacement (TAVR) technologies are currently available. Head-to-head comparisons of the relative performances of these 2 devices have been published. However, long-term clinical outcome evaluation remains limited by the number of patients analyzed, in particular, for recent-generation devices.<bold>Methods: </bold>Based on the French administrative hospital-discharge database, the study collected information for all consecutive patients treated with a TAVR device commercialized in France between 2014 and 2018. Propensity score matching was used for the analysis of outcomes during follow-up. The objective of this study was to analyze the outcomes of TAVR according to Sapien 3 balloon-expandable (BE) versus Evolut R self-expanding TAVR technology at a nationwide level in France.<bold>Results: </bold>A total of 31 113 patients treated with either Sapien 3 BE or Evolut R self-expanding TAVR were found in the database. After matching on baseline characteristics, 20 918 patients were analyzed (10 459 in each group with BE or self-expanding valves). During follow-up (mean [SD], 358 [384]; median [interquartile range], 232 [10-599] days), BE TAVR was associated with a lower yearly incidence of all-cause death (relative risk, 0.88; corrected P=0.005), cardiovascular death (relative risk, 0.82; corrected P=0.002), and rehospitalization for heart failure (relative risk, 0.84; corrected P<0.0001). BE TAVR was also associated with lower rates of pacemaker implantation after the procedure (relative risk, 0.72; corrected P<0.0001).<bold>Conclusions: </bold>On the basis of the largest cohort available, we observed that Sapien 3 BE valves were associated with lower rates of all-cause death, cardiovascular death, rehospitalization for heart failure, and pacemaker implantation after a TAVR procedure. [ABSTRACT FROM AUTHOR]
- Subjects :
- *HEART valve prosthesis implantation
*CARDIAC pacemakers
*AORTIC stenosis
*PROSTHETIC heart valves
*MEDICAL equipment design
*TREATMENT effectiveness
*DEATH
*PATIENT readmissions
*DATABASES
*RESEARCH
*RESEARCH methodology
*RETROSPECTIVE studies
*PROGNOSIS
*EVALUATION research
*MEDICAL cooperation
*COMPARATIVE studies
*HEART failure
*LONGITUDINAL method
Subjects
Details
- Language :
- English
- ISSN :
- 00097322
- Volume :
- 141
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Circulation
- Publication Type :
- Academic Journal
- Accession number :
- 142767699
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.119.043971